20:06 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Cell culture and mouse studies suggest adoptive transfer of CD56-expressing autologous or allogeneic NK cells could help treat ovarian cancer. Primary human NK cells cultured with IL-2 to induce activation and an IL-21-expressing...
19:21 , Nov 15, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers; other

TECHNOLOGY: Serum markers; computational models A computational model based on mucosal-associated invariant T cell expression of CCR6, CD56, CD25 and PD-1 in blood could help diagnose Type I diabetes. In peripheral blood samples from adult patients...
00:22 , Aug 31, 2017 |  BC Innovations  |  Translation in Brief

Fate’s killer memory

Fate Therapeutics Inc. has published the cell culture methodology behind Fate-NK100, its adoptive memory NK cell therapy in Phase I testing for cancer, and created two off-the-shelf versions of the candidate using iPS cells. According to...
07:00 , Aug 10, 2015 |  BC Week In Review  |  Clinical News

MVA-MUC1-IL2: Updated Phase IIb data

Updated data from a subgroup of 196 NSCLC patients with non-squamous tumors in the Phase IIb portion of the double-blind, international Phase IIb/III TIME trial showed that first-line treatment with subcutaneous TG4010 plus chemotherapy significantly...
07:00 , Jun 30, 2014 |  BC Week In Review  |  Clinical News

MVA-MUC1-IL2: Updated Phase IIb data

Updated data from 217 patients with MUC1-positive stage IV NSCLC in the Phase IIb portion of the double-blind, international Phase IIb/III TIME trial showed that first-line treatment with subcutaneous TG4010 plus chemotherapy met the primary...
08:00 , Jan 13, 2014 |  BC Week In Review  |  Clinical News

MVA-MUC1-IL2: Phase IIb data

Top-line data from 210 patients with MUC1-positive stage IV NSCLC in the Phase IIb portion of the double-blind, international Phase IIb/III TIME trial showed that first-line treatment with subcutaneous TG4010 plus chemotherapy missed the primary...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Clinical News

Lorvotuzumab mertansine: Phase II discontinued

ImmunoGen discontinued the open-label, international Phase II NORTH trial in over 135 patients with newly diagnosed SCLC after an analysis of available data by an independent DMC showed that first-line treatment with IMGN901 plus etoposide...
08:00 , Nov 11, 2013 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 11/8 cls Curis Inc. (NASDAQ:CRIS) BMO Capital Markets Jim Birchenough Downgrade Market perform...
08:00 , Nov 11, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Aeterna Zentaris Inc. (TSX:AEZ; NASDAQ:AEZS) was up C$0.01 to C$1.42 and unchanged at $1.35 on NASDAQ last week after submitting an NDA to FDA for Solorel macimorelin (AEZS-130) to diagnose adult growth hormone deficiency...
01:50 , Nov 6, 2013 |  BC Extra  |  Clinical News

ImmunoGen falls after stopping Phase II lung cancer trial

ImmunoGen Inc. (NASDAQ:IMGN) fell $3.14 (19%) to $13.41 on Tuesday after discontinuing on the recommendation of an independent DMC the Phase II NORTH trial, which was evaluating the company's IMGN901 to treat small cell lung...